Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.35 |
| ▸ | AGER | Q15109 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955568 | 1.00 | PTGS2 (0.41) | PTGS2PTGS1MEN1KMT2ALMNA | |
| SCHEMBL29569001 | 0.88 | PTGS2 (0.40) | PTGS2PTGS1MEN1KMT2ALMNA | |
| SCHEMBL5653976 | 0.87 | PTGS2 (0.41) | PTGS2PTGS1MEN1KMT2ALMNA | |
| SCHEMBL30716683 | 0.87 | PTGS2 (0.41) | PTGS2PTGS1MEN1KMT2ALMNA | |
| SCHEMBL29847479 | 0.85 | MAPT (0.46) | PTGS2PTGS1MEN1KMT2ALMNA | |
| SCHEMBL29956006 | 0.84 | GAA (0.45) | LMNAALDH1A1GAAAGERMAPT | |
| SCHEMBL992209 | 0.83 | ACHE (0.42) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL29954673 | 0.83 | GAA (0.38) | PTGS2PTGS1KMT2ALMNAALDH1A1 | |
| SCHEMBL31286083 | 0.83 | MAPT (0.38) | PTGS2PTGS1MEN1KMT2ALMNA | |
| SCHEMBL4833791 | 0.81 | CES2 (0.37) | NFE2L2CES2CES1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1070711-B1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1352906-A1 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Sankyo Company, Limited (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1243589-A1 | Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | PTGS2 119/4885PTGS1 147/4885MEN1 4780/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | PTGS2 116/4885PTGS1 159/4885MEN1 4759/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | PTGS2 88/4885PTGS1 78/4885MEN1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.